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ABSTRACT 
Background 
There is a lack of relevant prognostic and predictive factors in neurooncology 
besides mutation of isocitrate dehydrogenase (IDH)1, codeletion of 1p/19q and 
promoter hypermethylation of O6-methylguanine-DNA-methyltransferase (MGMT). 
More importantly, there is limited translation of these factors into clinical practice. 
The Cancer Genome Atlas (TCGA) data and also clinical correlative analyses 
suggest a pivotal role for the epidermal growth factor receptor (EGFR)/protein kinase 
B (AKT)/mammalian target of rapamycin (mTOR) pathway in both biology and the 
clinical course of gliomas. However, attempts to stratify gliomas by activating 
alterations in this pathway have failed thus far.  
 
Patients and methods 
The tumors of 40 patients with WHO grade II gliomas without immediate 
postoperative genotoxic treatment and known progression and survival status at a 
median follow-up of 12.2 years were analyzed for expression of the mTOR complex 
(mTORC)2 downstream target N-myc downstream regulated gene (NDRG)1 using 
immunohistochemistry. 
 
Results 
Baseline characteristics for NDRG1 absent/low versus moderate/high patients were 
similar. Time to reintervention was significantly longer in the NDRG1 group 
(P=0.026). 
 
Conclusions 
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NDRG1 may become a novel biomarker to guide the decision which WHO°II glioma 
patients may be followed without postsurgical intervention and which patients should 
receive genotoxic treatment early on. Validation of this hypothesis will be possible 
with the observational arm of the RTOG 9802 and the pretreatment step of the 
EORTC 22033/26032 trials. 
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INTRODUCTION 
Mutations of the isocitrate dehydrogenase (IDH) gene 1 were first identified in human 
gliomas as a result of a large-scale genomic sequencing approach [1]. This has been 
confirmed across gliomas of World Health Organization (WHO) grades II-IV, 
including both astrocytic and oligodendroglial tumors [2-4]. However, most studies 
have failed to link IDH1 mutations to better responsiveness to specific types of 
treatment, neither in glioblastoma [5], anaplastic glioma [2,6] nor low-grade glioma 
[7].  
Although diagnoses of gliomas are based on histology, molecular abnormalities 
known to occur in these tumors have been evolving as supportive markers to assist 
diagnostics and patient management. Besides IDH1 mutations, these markers in 
WHO grade II gliomas are O6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation status, deletions involving chromosomes 1p and 19q, and 
mutations in the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) oncogene 
have moved into the focus of scientific interest and are already implemented in 
routine diagnostic workup. To evaluate the clinical relevance of these markers, it is 
crucial to distinguish the prognostic significance, defined as overall better outcome 
irrespective of management, from the predictive significance, defined as a better 
outcome given a specific treatment is administered [8].  
Hypermethylation of the MGMT gene promoter for malignant gliomas and codeletion 
of 1p/19q for anaplastic oligodendroglial tumors are the only biomarkers linked to 
sensitivity to a specific treatment, that is, alkylating chemotherapy, specifically 
temozolomide (TMZ) for MGMT [9,10] and the combination of procarbazine, 1-(2-
chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and vincristine (PCV) for 1p/19q 
codeletion [11,12]. Until recently, it was believed that the predictive value of MGMT 
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promoter methylation may be limited to glioblastoma since anaplastic gliomas 
showed a more favorable course of disease with a hypermethylated MGMT promoter 
in both alkylator- and also radiotherapy-treated patients [2, 11]. Interaction analyses 
between IDH1 and MGMT, however, have revealed that MGMT promoter 
methylation is probably a predictive biomarker for response to chemotherapy in 
patients with IDH1 wild-type, but not IDH1 mutant gliomas, irrespective of WHO 
grade [13]. All currently known biomarkers unravel their prognostic properties only if 
genotoxic treatment is used and none of the biomarkers discussed so far, including 
IDH or TP53 status, MGMT promoter hypermethylation or 1p/19q codeletion, show a 
good relation to the natural course of disease [8,14]. In low-grade gliomas, guidance 
whether a patient with a newly diagnosed tumor needs early genotoxic treatment or 
not is pivotal, as the most commonly used treatment, radiotherapy of the involved 
part of the brain [15], is not associated with an overall survival (OS) benefit but 
possibly with long-term adverse sequelae especially in patients with a favorable 
prognosis [16]. 
The mTORC2-pathway effector, N-myc downstream regulated gene (NDRG)1, has 
been proposed as a prognostic factor in tumors including gliomas [17], although 
prognostic relevance in either direction has been described. Most recently, recurrent 
translocations of the oncogene plasmocytoma variant translocation (PVT)1, including 
PVT1-MYC and PVT1-NDRG1, have been described as potential targets in group 3 
medulloblastoma [18]. 
Initial experiments assessing the role of NDRG1 in basic in vitro and in vivo 
proliferation paradigms surprisingly revealed growth-limiting properties of NDRG1 
expression [19]. From that, we hypothesized that World Health Organization (WHO)  
grade II gliomas with a differential postoperative course of disease can be separated 
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on the basis of the expression of the mTORC2 downstream target, NDRG1, which 
then may serve as a biomarker for the decision to treat or to perform a watch-and-
wait strategy. 
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Materials and methods 
Patients and evaluations – German Glioma Network (GGN) cohort 
The GGN is a prospective cohort study that enrolled newly diagnosed patients with 
various types of glioma and frozen tissue asservation from October 2004 to October 
2010. From this cohort, we identified 40 patients with a diagnosis of a supratentorial 
WHO grade II astrocytoma or oligodendroglial tumor confirmed by history taking and 
central pathology review [20], as well as adequate follow-up at least until 
progression, who were followed by a watch-and-scan policy according to 
investigators’ discretion supported by risk factor profiles [21]. Some of these patients 
were included in previous publications addressing the same clinical correlative 
question, but assessing different markers [8,14]. Clinical data were prospectively 
assembled as outlined before (http://www.gliomnetzwerk.de) [5]. All patients gave 
written informed consent. All activities of the GGN have been approved by the review 
boards of the participating institutions.  
 
Molecular methods 
1p/19q deletion status, MGMT promoter methylation as well as IDH and TP53 
mutational status have been determined as described previously [8,14]. 
 
Immunohistochemistry 
Formalin-fixed paraffin-embedded tissue of 40 human grade II gliomas from the 
German Glioma Network (GGN) [8,14] was employed for immunohistochemical 
analysis for NDRG1 (goat anti-NDRG1 at 1:1000, Abcam, Cambridge, England, UK) 
on 3 µm sections. For quantitative analysis of the staining pattern by an independent 
neuropathologist blinded to the clinical data, the Histo-Score by Bruna et al. was 
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applied [22]. The score ranges from 0 to 300 and is calculated as the percentage of 
weakly stained cells plus the percentage of moderately stained cells multiplied by 
two plus the percentage of strongly stained cells multiplied by three. The entire tumor 
section was assessed except for areas not distinguishable from reactive tissue (Fig. 
1). Ki67 immunostaining was done with an anti-Ki67 (MIB-1, mouse monoclonal 
antibody, Flex TRS low, 1:200 dilution, Dako, Glostrup, Denmark). For assessment 
of the proliferation index, anti-Ki67 immunostained tumors sections were scanned at 
low magnification to identify an area with high labelling density. In this area, 500 
tumor cell nuclei were evaluated. The fraction of labelled nuclei per 500 tumor cell 
nuclei was determined by manual counting and is expressed as a percentage. 
 
Statistical analysis  
Survival data for NDRG1 low (0-10) or intermediate/high (>10-300) were plotted by 
the Kaplan-Meier method and analyzed by the log-rank test. Multivariate analysis of 
progression-free survival (PFS) used Cox proportional hazards models to adjust for 
the following clinical data and molecular markers: histological tumor type, resection 
status, age in years, IDH1 status and MGMT promoter methylation status. Survival 
analyses were performed by B.H. using IBM SPSS Statistics Version 20.  
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RESULTS 
Baseline clinical and molecular characteristics and NDGR1 expression 
To assess whether the postoperative course of disease in WHO grade II glioma 
patients shows an association with NDRG1 expression, we took advantage of a 
series of patients who received no immediate radiotherapy or chemotherapy after the 
diagnosis had been established as part of a surgical intervention. The patients were 
assigned to two different groups: NDRG1 absent/low versus NDRG1 moderate/high 
as illustrated in Fig. 1. The two groups were well balanced with respect to age, post-
operative KPS, histological subtype, Ki67 labelling, 1p/19q status, IDH status, TP53 
status, but there was an overrepresentation of gross total resections and MGMT 
promoter hypermethylation in the NDRG1 absent/low group (Table 1).  
 
High NDRG1 levels are associated with longer time to intervention, but not 
overall survival 
After a median follow-up of 146 months, 40 patients have progressed (100%) and 26 
patients (65%) have died. At progression, 24 patients were treated with radiotherapy, 
10 patients with chemotherapy, and 6 patients with combined modality treatment. 
In the univariate analysis oligodendroglial histology and moderate/high NDRG1 
expression were associated with a strong risk reduction for progression (Table 2). 
Moderate/high NDRG1 expression was associated with superior PFS [NDRG1 low: 
median PFS 30 months (95% confidence interval 12-48 months)] versus [NDRG1 
medium/high: median PFS 54 months (95% confidence interval 24-84 months)] (Fig. 
2a). Of note, the effect of NDRG1 was present also in analyses separated for 
astrocytic and oligodendroglial histologies without differential impact. On multivariate 
analysis, oligodendroglial histology (HR 0.3 95% CI (0.1-0.6), P=0.001) and 
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moderate/high NDRG1 expression (HR 0.4, 95% CI (0.2-0.8, P=0.01) persisted as 
strong prognostic factors (Table 2). 
For OS, however, i.e. after one or more genotoxic treatments, which included 
sequential radiotherapy and alkylating chemotherapy in either order in all patients, 
only age was prognostic (<40 years versus ≥40 years, P<0.05) and the two NDRG1 
groups did not differ anymore (Fig. 2b). Due to the lack of archival data to confirm 
our findings, we just took the opportunity to check for the potential negative impact 
on OS in patients that had undergone radiochemotherapy. Analysis of the 
REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) database revealed 
that the OS of glioblastoma patients with intratumoral upregulation of NDRG1 was 
reduced compared to patients with intermediate or downregulated expression of this 
gene (Fig. 2c). 
 
These data indicate that moderate/high NDRG1 expression is an independent 
prognostic factor for favorable outcome in patients with WHO grade II gliomas not 
exposed to postsurgical treatment.  
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DISCUSSION  
Despite relevant progress in the field of molecular classification of malignant 
gliomas, all attempts to define a parameter, which predicts the natural course of 
disease in low-grade gliomas, have failed thus far. Patients with these tumors are 
currently treated or followed based on the set of prognostic parameters developed 
from the EORTC 22844 trial [21], but still a lot of uncertainty for individual treatment 
decisions remains. From this set of parameters, oligodendroglial histology has been 
confirmed here as prognostic for PFS without postsurgical intervention (Table 2). 
Analyses of the prognostic potential of 1p/19q codeletion, IDH1 mutation and MGMT 
promoter hypermethylation revealed a prognostic or predictive potential of these 
markers only when radio- or chemotherapy were used [5,8,14]. In addition, there are 
molecular alterations like duplications or mutations of the v-raf murine sarcoma viral 
oncogene homolog B1 (BRAF) that not only define a specific glioma entity, but may 
also be linked to a specific therapy [23]. There is an unmet need for molecular 
markers with prognostic impact in the immediate postsurgical situation [24] that 
facilitate daily decision-making in the clinic.  
Despite its name, NDRG1 is neither regulated by nor correlated to N-Myc in glioma 
[19]. NDRG1 has been described as a hypoxia-inducible protein in glioblastoma, 
whose expression is associated with increasing malignancy in gliomas, peaking out 
in relapsed glioblastomas following radiochemotherapy [19]. Our survival analysis on 
postsurgically untreated WHO °II gliomas demonstrate an NDRG1-associated 
growth delay and thus an improved PFS in a multivariate analysis (Fig. 2a), which 
was not visible any more at OS when genotoxic treatments had been applied (Fig. 
2b). Due to a lack of a confirmatory data set, we only confirmed the negative 
prognostic impact of NDRG1 mRNA expression when treatments are applied (Fig. 
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2c). These data allow a separation of disease- and treatment-modifying effects and 
support a tumor-suppressing function of NDRG1, which is limiting tumorigenicity in 
the natural course of the disease. Further, the other biomarkers discussed in glioma, 
1p/19q, IDH1, MGMT, Ki67 labelling [8,14], hot spot mutations in the promoter region 
of telomerase reverse transcriptase (TERT) [25] and mutation/loss of alpha-
thalassemia/mental retardation syndrome X-linked (ATRX) expression [26] show a 
good relation to the natural course of disease, but unravel their prognostic properties 
only if cytotoxic treatment is applied. This prevents their use to categorize tumors 
and also to determine more favorable subgroups of tumors, in which a wait-and-scan 
strategy after surgery might be better than immediate cytotoxic treatment. The size 
of our patient cohort prevents further subgroup analyses. In this cohort, no 
interaction between tumor type, 1p/19q codeletion, IDH1 mutation or MGMT 
promoter methylation and NDRG1 expression was found. Of note, although no 
significant differences are found between the two NDRG1 expression groups, 
positive risk factors, specifically gross total resection, are numerically higher 
represented in the NDRG1 no/low group, and therefore bias against our finding 
(Table 1). 
Outside the brain tumor field, the relevance of NDRG1 depends on the tumor entity. 
NDRG1 suppresses the proliferation of breast cancer cells in vitro [27] and the tumor 
growth of pancreatic and bladder cancer in vivo [27,28], whereas survival and 
proliferation of hepatocellular carcinoma cells are promoted [29]. In line with these 
preclinical findings NDRG1 expression is associated with a favorable prognosis in 
patients with breast, colon or pancreatic cancer [28,30,31], but associated with more 
aggressive disease in cervical or liver cancer [32,33]. In these studies, effects on 
tumor growth and therapy-modifying properties of NDRG1 are not separable.    
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In summary, NDRG1 may serve as the first prognostic biomarker for the natural 
course of disease in WHO grade II gliomas that awaits validation in the analyses of 
the observational arm of RTOG 9802 and the registration step of the EORTC 
22033/26032 WHO grade II glioma trials.   
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FIGURE LEGENDS 
Figure 1. Histoscore for NDRG1 
(a) NDRG1 immunohistochemistry in a case of moderate staining (histo score group 
>10, left) and a case with absence of NDRG1 expression (histo score group <10). 
Note staining of the tumor cell processes (arrows) and the decreasing staining of 
tumor matrix apart from strongly positive areas (arrowheads). (b) Representative 
cases illustrating the application of an adapted histo score 22 for evaluation of 
NDRG1 staining on paraffin-embedded glioma sections. The score ranges from 0 to 
300 and is calculated as the percentage of weakly stained cells plus the percentage 
of moderately stained cells multiplied by two plus the percentage of strongly stained 
cells multiplied by three (positive cells are stained red and an isotype control (c) is 
provided). The entire tumor section was assessed except for areas not 
distinguishable from reactive tissue.  
 
Figure 2. NDRG1 expression prognosticates superior PFS in postsurgically 
untreated WHO grade II gliomas 
(a) PFS and (b) OS data of 40 patients with a WHO grade II glioma without 
postsurgical treatment until further progression are plotted in the group no/low or 
moderate/high expression of NDRG1 in the tumor tissue. Scoring and grouping was 
done by an independent neuropathologist (FS) blinded to PFS or OS data. (c) 
NDRG1 expression relative to patient survival in glioblastoma (REMBRANDT). 
 
 


